IDYA (IDEAYA Biosciences) Gross Margin %: 0.00% (As of Mar. 2026)


IDYA IDEAYA Biosciences Inc IDYA
55 GF Score
Price $36.67
GF Value $214.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is IDEAYA Biosciences Gross Margin %?

IDEAYA Biosciences IDYA +5.15% 55 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates IDYA with a GF Score™ of 55/100 and a GF Value™ of $214.33 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 738 Biotechnology companies, IDEAYA Biosciences ranks worse than 135501.22% on this metric.

Gross Margin % is calculated as gross profit divided by its revenue. IDEAYA Biosciences's Gross Profit for the three months ended in Mar. 2026 was $6.6 Mil. IDEAYA Biosciences's Revenue for the three months ended in Mar. 2026 was $6.6 Mil. Therefore, IDEAYA Biosciences's Gross Margin % for the quarter that ended in Mar. 2026 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for IDEAYA Biosciences's Gross Margin % or its related term are showing as below:


IDYA's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.94
* Ranked among companies with meaningful Gross Margin % only.

IDEAYA Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for IDEAYA Biosciences was 0.00% per year.


IDEAYA Biosciences  (NAS:IDYA) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IDEAYA Biosciences had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


IDEAYA Biosciences Gross Margin % Related Terms


IDEAYA Biosciences Gross Margin % Historical Data

* Premium members only.

The historical data trend for IDEAYA Biosciences's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEAYA Biosciences Gross Margin % Chart

IDEAYA Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Gross Margin %
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

IDEAYA Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

IDYA vs MLYS, TARS, DFTX: Gross Margin % Comparison

For the Biotechnology subindustry, IDEAYA Biosciences's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEAYA Biosciences Gross Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IDEAYA Biosciences's Gross Margin % distribution charts can be found below:

* The bar in red indicates where IDEAYA Biosciences's Gross Margin % falls into.


IDYA
55GF Score
IDEAYA Biosciences Inc IDYA
Gross Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEAYA Biosciences Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

IDEAYA Biosciences's Gross Margin for the fiscal year that ended in Dec. 2025 is calculated as

Gross Margin % (A: Dec. 2025 )=Gross Profit (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=218.7 / 218.71
=(Revenue - Cost of Goods Sold) / Revenue
=(218.71 - 0) / 218.71
=N/A %

IDEAYA Biosciences's Gross Margin for the quarter that ended in Mar. 2026 is calculated as


Gross Margin % (Q: Mar. 2026 )=Gross Profit (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=6.6 / 6.56
=(Revenue - Cost of Goods Sold) / Revenue
=(6.56 - 0) / 6.56
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Frequently Asked Questions Learn more about Gross Margin % →
What does a Gross Margin % of 0.00% mean?
IDEAYA Biosciences (IDYA) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on IDEAYA Biosciences and its competitors. According to the industry distribution chart, IDEAYA Biosciences ranks #999999 out of 738 companies in the Biotechnology industry.
Is IDEAYA Biosciences' Gross Margin % too high?
IDEAYA Biosciences' current Gross Margin % is 0.00%. Based on the distribution chart, IDEAYA Biosciences ranks #999999 out of 738 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, IDEAYA Biosciences has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IDEAYA Biosciences' Gross Margin % compare to MLYS and TARS?
According to the Biotechnology industry distribution chart, IDEAYA Biosciences ranks #999999 out of 738 companies for Gross Margin %. This places IDEAYA Biosciences in the lower half of its industry. The industry median Gross Margin % is 60.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on IDEAYA Biosciences and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDEAYA Biosciences's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEAYA Biosciences stock overvalued right now?
Based on GuruFocus' analysis, IDEAYA Biosciences (IDYA) is currently considered Possible Value Trap. The stock's GF Value™ is $214.33, compared to a current price of $36.67 — trading 82.9% below its estimated fair value. The current Gross Margin % is 0.00%. IDEAYA Biosciences' overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For IDEAYA Biosciences (IDYA), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEAYA Biosciences (IDYA) Overvalued in 2026?

Based on GuruFocus' analysis, IDEAYA Biosciences stock appears to be undervalued. The current stock price of $36.67 is trading 82.9% below its estimated GF Value™ of $214.33. GuruFocus considers IDEAYA Biosciences to be Possible Value Trap.

Key valuation signals for IDYA:

  • Gross Margin %: 0.00%
  • GF Value™: $214.33 vs. price of $36.67 (82.9% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the IDYA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEAYA Biosciences Business Description

Other Exchanges 30J:Germany
Address 5000 Shoreline Court, Suite 300, South San Francisco, CA, USA, 94080
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
55GF Score

Get the complete analysis for IDYA

Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.67
Price
$214.33
GF Value